<a href="https://laohu8.com/S/ZVSA">Zyversa Therapeutics</a> Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements
ZyVersa Therapeutics Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550(a)(2). Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol "ZVSA." This move might pose challenges for stockholders due to a potentially limited market for trading shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019856), on July 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。